Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14840610 | 0.88 | STIM1 (0.43) | NR3C2NR3C1PGRSTIM1ORAI1 | |
| SCHEMBL14841351 | 0.86 | STIM1 (0.36) | NR3C2SCN9ASTIM1ORAI1ATR | |
| SCHEMBL14840965 | 0.81 | HTR2C (0.32) | — | |
| SCHEMBL14840530 | 0.73 | LTB4R (0.37) | NR3C2NR3C1PGR | |
| SCHEMBL14840526 | 0.73 | LTB4R (0.38) | NR3C2NR3C1PGR | |
| SCHEMBL14840629 | 0.73 | LTB4R (0.38) | NR3C2NR3C1PGR | |
| SCHEMBL14840525 | 0.73 | LTB4R (0.38) | NR3C2NR3C1PGR | |
| SCHEMBL14840436 | 0.71 | NR3C2 (0.42) | NR3C2NR3C1PGRSTIM1ORAI1 | |
| SCHEMBL12826349 | 0.71 | STIM1 (0.45) | NR3C2SCN9ASTIM1ORAI1 | |
| SCHEMBL14840695 | 0.70 | CYP11B2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | claimed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | claimed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | RYR2, CACNA1E, RYR1 | NR3C2 1678/4885SCN9A 349/4885NR3C1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.